| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
|
Kater, Arnon P
|
|
|
25 |
4 |
p. 463-473
|
artikel
|
| 2 |
Alabama Supreme Court's “extrauterine children” decision alarms oncologists and fertility experts
|
Furlow, Bryant
|
|
|
25 |
4 |
p. 423-424
|
artikel
|
| 3 |
A new era of risk prediction for patients with high-risk melanoma
|
Olofsson Bagge, Roger
|
|
|
25 |
4 |
p. 415-416
|
artikel
|
| 4 |
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study
|
Kim, Stefano
|
|
|
25 |
4 |
p. 518-528
|
artikel
|
| 5 |
Cancer control collaborations between China and African countries
|
Ngoma, Twalib
|
|
|
25 |
4 |
p. e164-e172
|
artikel
|
| 6 |
Combining chemotherapy and immunotherapy for advanced anal cancer: are we ready?
|
Martinelli, Erika
|
|
|
25 |
4 |
p. 416-417
|
artikel
|
| 7 |
Correction to Lancet Oncol 2023; 24: 1399–410
|
|
|
|
25 |
4 |
p. e137
|
artikel
|
| 8 |
Correction to Lancet Oncol 2024; 25: 317–25
|
|
|
|
25 |
4 |
p. e137
|
artikel
|
| 9 |
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis
|
Goulart, Bernardo Haddock Lobo
|
|
|
25 |
4 |
p. 455-462
|
artikel
|
| 10 |
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study
|
Del Paggio, Joseph C
|
|
|
25 |
4 |
p. 431-438
|
artikel
|
| 11 |
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis
|
Stassen, Robert C
|
|
|
25 |
4 |
p. 509-517
|
artikel
|
| 12 |
68Ga-RM2 PET–MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial
|
Duan, Heying
|
|
|
25 |
4 |
p. 501-508
|
artikel
|
| 13 |
Gastric signet-ring cell adenocarcinoma masquerading as sarcoidosis
|
Belkaïd, Samy
|
|
|
25 |
4 |
p. e173
|
artikel
|
| 14 |
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
|
Layman, Rachel M
|
|
|
25 |
4 |
p. 474-487
|
artikel
|
| 15 |
Indonesia and the Philippines take steps to control cancer
|
Das, Manjulika
|
|
|
25 |
4 |
p. 421
|
artikel
|
| 16 |
Innovation in gynaecological cancer: highlighting global disparities
|
Kyrgiou, Maria
|
|
|
25 |
4 |
p. 425-430
|
artikel
|
| 17 |
Intellectual and developmental disabilities—an under-recognised driver of cancer mortality
|
The Lancet Oncology,
|
|
|
25 |
4 |
p. 411
|
artikel
|
| 18 |
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
|
Musher, Benjamin L
|
|
|
25 |
4 |
p. 488-500
|
artikel
|
| 19 |
Massive US cybersecurity breach highlights perils of health-care consolidation
|
Furlow, Bryant
|
|
|
25 |
4 |
p. e138
|
artikel
|
| 20 |
Non-communicable diseases in humanitarian settings
|
Burki, Talha
|
|
|
25 |
4 |
p. 422
|
artikel
|
| 21 |
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
|
Browne, Iseult M
|
|
|
25 |
4 |
p. e139-e151
|
artikel
|
| 22 |
South Africa combats gaps in cancer data
|
Das, Manjulika
|
|
|
25 |
4 |
p. 420
|
artikel
|
| 23 |
The cost and value of cancer medicines in Ontario, Canada
|
Longo, Christopher J
|
|
|
25 |
4 |
p. 412-413
|
artikel
|
| 24 |
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions
|
Schlander, Michael
|
|
|
25 |
4 |
p. e152-e163
|
artikel
|
| 25 |
Towards world-class radiotherapy in the UK: time for transformation
|
Wakeham, Katie
|
|
|
25 |
4 |
p. 418-419
|
artikel
|
| 26 |
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
|
Smit, Egbert F
|
|
|
25 |
4 |
p. 439-454
|
artikel
|
| 27 |
Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia
|
Yang, Lin
|
|
|
25 |
4 |
p. 413-414
|
artikel
|
Tijdschrift beschrijving